

What Is Claimed Is:

Subj 2 1. A conjugate of a non-immunogenic toxin or therapeutic radionuclide and a cell-specific cytokine.

C 2. A conjugate as claimed in claim 1, wherein said toxin is an RNase.

B 3. A conjugate as claimed in claim 1, wherein said cytokine is IL-15.

M Col 4 4. A conjugate as claimed in claim 3, wherein said toxin is onconase.

5. 5. A conjugate as claimed in claim 4, which additionally comprises a diagnostic radionuclide.

6. 6. A composition comprising a conjugate according to claim 1, and a pharmaceutically acceptable carrier.

7. 7. A composition as claimed in claim 6, additionally comprising a diagnostic radionuclide conjugated to said cytokine.

8. 8. A fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α .

9. 9. A fusion protein as claimed in claim 8, wherein said bispecific antibody is a scF_v.

10. 10. A fusion protein as claimed in claim 9, wherein said scF_v is a fusion of two individual scF_v molecules.

11. 11. A fusion protein as claimed in claim 8, wherein said cell marker is a B-cell restricted antigen.

20
22

11
12. A fusion protein as claimed in claim 11, wherein said cell marker is CD20.

13
14. A fusion protein as claimed in claim 8, wherein said region of IL-15 α is an extracellular domain of IL-15 α .

15
16. A composition comprising a fusion protein according to claim 8 and a pharmaceutically acceptable carrier.

Subra 3 15. A kit comprising a conjugate of onconase and IL-15, and a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α .

16. A method of treating a malignancy, comprising the steps of: first administering to a subject having a malignancy a fusion protein comprising a bispecific antibody that has a first specificity for a cell marker specific to a malignant cell and a second specificity for a region of IL-15 α , and then administering to said subject therapeutically effective amount of a conjugate of onconase and IL-15.

17. A method as claimed in claim 16, additionally comprising a step of administering at least one of chemotherapy and radiation therapy in an amount sufficient to prevent tumor cells from activating DNA-repair mechanisms.

18. A method as claimed in claim 16, wherein said cell marker is a B-cell restricted antigen and said subject has a B-cell malignancy.

19. A method as claimed in claim 18, wherein said cell marker is CD20 and said subject has B-cell lymphocytic leukemia, non-Hodgkin's lymphoma, hairy cell leukemia or acute myelogenous leukemia.

Add a 4

11